International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
- 1 October 2005
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 24 (10), 654-661
- https://doi.org/10.1007/s10096-005-0024-8
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolatesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in JapanScandinavian Journal of Infectious Diseases, 2004
- High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective studySupportive Care in Cancer, 2004
- Guidelines for Treatment of CandidiasisClinical Infectious Diseases, 2004
- MicafunginDrugs, 2004
- Voriconazole Salvage Treatment of Invasive CandidiasisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Echinocandin antifungal drugsThe Lancet, 2003
- Mortality and Costs of Acute Renal Failure Associated with Amphotericin B TherapyClinical Infectious Diseases, 2001
- Practice Guidelines for the Treatment of CandidiasisClinical Infectious Diseases, 2000
- Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997